Advancements in DLBCL Therapies Fuel Market Momentum Through 2034

The Diffuse Large B-cell Lymphoma (DLBCL) market across leading markets—the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan—was valued at USD 4.7 billion in 2024 and is projected to expand at a CAGR of ~13% through 2034, driven by rapid innovation in CAR-T therapies, bispecific antibodies, antibody–drug conjugates (ADCs), and targeted immunotherapies. The US market alone is expected to surpass USD 11.5 billion by 2034.

According to DelveInsight’s Diffuse Large B-cell Lymphoma Market Insights report, this growth is underpinned by rising disease incidence, an aging population, improved diagnostics, and the earlier-line adoption and label expansion of advanced immunotherapies, including CAR-T cells and CD20/CD3 bispecific antibodies.

Stay ahead in Diffuse Large B-Cell Lymphoma competitive intelligence: https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Diffuse Large B-Cell Lymphoma Market Landscape and Treatment Paradigm

DLBCL remains the most common subtype of non-Hodgkin lymphoma. While R-CHOP continues to be the standard first-line regimen, approximately 40% of patients relapse or develop refractory disease, creating a substantial opportunity for innovative therapies.

The relapsed/refractory (R/R) DLBCL segment is the primary growth engine of the market, fueled by:

• FDA-approved CAR-T therapies such as YESCARTA (Gilead/Kite), BREYANZI (BMS), and KYMRIAH (Novartis)
• Bispecific antibodies including EPKINLY (epcoritamab) and COLUMVI (glofitamab), which are gaining rapid clinical uptake
• Antibody–drug conjugates and next-generation immunotherapies targeting CD19, CD20, CD30, and novel intracellular pathways

Emerging therapies such as Zilovertamab vedotin (Merck), Golcadomide (BMS), Zamtocabtagene autoleucel (Miltenyi Biomedicine), Rapcabtagene autoleucel (Novartis), and Cemacabtagene ansegedleucel (Allogene Therapeutics) are expected to significantly reshape the competitive landscape by 2034.

Key Growth Diffuse Large B-Cell Lymphoma Market Drivers

Rising Incidence and Aging Demographics

• Global DLBCL incidence exceeds 150,000 cases annually
• In the 7MM, incident cases are projected to reach ~87,000 by 2034

Innovation in Targeted and Immune-Based Therapies

• Expansion of CAR-T, bispecific antibodies, and ADCs
• Movement of advanced therapies into earlier treatment lines

Strong R&D and Clinical Trial Momentum

• Over 30 biopharma companies actively developing DLBCL therapies, including Roche, BMS, AstraZeneca, Merck, Novartis, Gilead, Pfizer, Regeneron, BeiGene, and Amgen

Improved Diagnostics and Risk Stratification

• Adoption of PET-CT and next-generation sequencing (NGS) has increased early detection rates by nearly 20%, improving outcomes and expanding the treatable population.

Unlock detailed analysis of Diffuse Large B-Cell Lymphoma clinical trials

Diffuse Large B-Cell Lymphoma Clinical Trial Sponsorship and Innovation

While North America and Europe dominate commercial revenues, Asia—particularly Japan and South Korea—is emerging as a critical hub for DLBCL clinical development, contributing regional data and novel therapeutic approaches.

Expanding ADC and Chemotherapy-Based Strategies

• Drug: MT-2111 (CD19-targeted ADC)
• MOA: Delivers a cytotoxic payload to CD19-expressing B cells, similar to loncastuximab tesirine
• Clinical Development:
  • Phase 1/2 (NCT05658562): Ongoing in R/R DLBCL
  • Phase 3: Global confirmatory trial of MT-2111 + rituximab, with Japan actively participating
• Strategic Significance: Supports PMDA regulatory engagement and potential regional approval

SymBio Pharmaceuticals (Japan)

• Drug: SyB L-0501 (bendamustine hydrochloride; TREAKISYM®)
• MOA: DNA-alkylating agent inducing apoptosis in malignant B cells
• Clinical Status:
  • Phase I–III combination studies with rituximab in DLBCL completed
• Current Position: Widely used in Japan for lymphoma, though no ongoing late-stage DLBCL expansion trials were identified

Domestic CAR-T Innovation

• Drug: Anbal-cel (next-generation CD19 CAR-T)
• MOA: Autologous CAR-T enhanced with OVIS™ technology to reduce PD-1/TIGIT expression and improve persistence
• Clinical Development:
  • Phase 2: Completed in R/R DLBCL with ~71% complete response rate
• 2025 Outlook:
  • Planned BLA submission to Korea’s MFDS
  • Potential commercial launch as early as 2025, positioning Anbal-cel as Korea’s first domestically developed CAR-T for DLBCL

Limited DLBCL-Specific Trial Activity

At present, no Taiwan-based companies were identified as sponsors of active Phase 1–3 DLBCL clinical trials. While firms such as OBI Pharma, Adimmune, and Daiken Bio maintain oncology or biologics pipelines, their current activities do not include registered DLBCL-focused studies.

Diffuse Large B-Cell Lymphoma Regional Clinical Trial Snapshot

Discover how regulatory approvals and label expansions are transforming the Diffuse Large B-Cell Lymphoma treatment market

Diffuse Large B-Cell Lymphoma Outlook

The DLBCL market is entering a transformative decade, marked by the convergence of cell therapy, bispecific antibodies, and precision immuno-oncology. While the US and Europe will remain commercial anchors, Japan’s ADC and combination strategies and South Korea’s CAR-T innovation are increasingly influential in shaping global development pathways.

As regulatory milestones are achieved and next-generation therapies move into earlier lines of treatment, the DLBCL market is well positioned for sustained double-digit growth through 2034, reinforcing its status as one of the most dynamic segments in hematologic oncology.

Gain in-depth insights into the evolving Diffuse Large B-Cell Lymphoma market

Table of Contents

1. DLBCL Market Key Insights

2. DLBCL Market Report Introduction

3. DLBCL Market Executive Summary

4. Key Events

4.1 Upcoming Key Catalyst

4.2 Key Transactions and Collaborations

4.3 News Flow

4.4 ASCO, ESMO, and Other Latest DLBCL Conference Highlights

5. DLBCL Epidemiology and DLBCL Market Forecast Methodology

6. DLBCL Market Overview at a Glance in the 7MM

6.1 DLBCL Market Share (%) Distribution by Line of Therapies in 2024

6.2 DLBCL Market Share (%) Distribution by Line of Therapies in 2034

6.3 DLBCL Market Share (%) Distribution by Class in 2024

6.4 DLBCL Market Share (%) Distribution by Class in 2034

7. Disease Background and Overview

7.1 Introduction

7.2 Understanding Lymphoma

7.3 Signs and Symptoms of DLBCL

7.4 Pathogenesis

7.5 Classification of DLBCL

7.6 WHO Classification of DLBCL

7.7 DLBCL Diagnosis

7.8 Differential Diagnosis

7.9 Staging

7.10 DLBCL Biomarkers

8. Guidelines

8.1 National Comprehensive Cancer Network (NCCN) Treatment Guidelines for DLBCL

8.2 ESMO Clinical Practice Guidelines for Diagnosis

8.3 Japanese Society of Hematology (JSHEM) Guidelines for DLBCL

9. Epidemiology and Patient Population of the 7MM

9.1 Key Findings

9.2 Assumptions and Rationale

9.3 Total Incident Cases of DLBCL in the 7MM

9.4 The United States

9.4.1 Total Incident Cases of DLBCL in the US

9.4.2 Gender-specific Cases of DLBCL in the US

9.4.3 Age-specific Cases of DLBCL in the US

9.4.4 Type-specific Cases of DLBCL in the US

9.4.5 Stage-specific Incident Cases of DLBCL in the US

9.5 EU4 and the UK

9.6 Japan

10. DLBCL Patient Journey

11. Key Endpoints in DLBCL

12. Marketed DLBCL Drugs

12.1 Key Cross-competition of DLBCL Therapies

12.2 RITUXAN/MABTHERA (rituximab): Biogen/Genentech/Roche

12.2.1 Product Description

12.2.2 Regulatory Milestones

12.2.3 Other Developmental Activities

12.2.4 Safety and Efficacy

12.2.5 Analyst Views on DLBCL Drugs

12.3 TREAKISYM (bendamustine hydrochloride): SymBio Pharmaceuticals

12.4 EPKINLY/TEPKINLY (epcoritamab-bysp): Genmab & AbbVie

12.5 COLUMVI (glofitamab-gxbm): Roche/Genentech

12.6 ORDSPONO (odronextamab): Regeneron Pharmaceuticals

12.7 KEYTRUDA (pembrolizumab): Merck

12.8 MONJUVI/MINJUVI (tafasitamab-cxix): MorphoSys/Incyte

12.9 ZYNLONTA (loncastuximab tesirine-lpyl): ADC Therapeutics/SOBI

12.10 ADCETRIS (brentuximab vedotin): Pfizer & Takeda

12.11 POLIVY (polatuzumab vedotin-piiq): Roche/Genentech/Chugai

12.12 YESCARTA (axicabtagene ciloleucel): Kite Pharma (Gilead)

12.13 BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb

12.14 KYMRIAH (tisagenlecleucel): Novartis

12.15 XPOVIO (selinexor): Karyopharm Therapeutics

13. Emerging DLBCL Drugs

13.1 Key Competitors

13.2 Zilovertamab Vedotin (MK-2140): Merck

13.2.1 Product Description

13.2.2 Other Developmental Activities

13.2.3 Clinical Development in DLBCL

13.2.4 Safety and Efficacy

13.2.5 Analyst Views

13.3 CALQUENCE (acalabrutinib): AstraZeneca

13.4 LUNSUMIO (mosunetuzumab): Roche/Genentech & Biogen

13.5 NKTR-255: Nektar Therapeutics

13.6 Cemacabtagene ansegedleucel (cema-cel): Allogene Therapeutics

13.7 Golcadomide (BMS-986369): Bristol Myers Squibb (Celgene)

13.8 Maveropepimut-S (MVP-S): BioVaxys/ImmunoVaccine

13.9 Zamtocabtagene Autoleucel (MB-CART2019.1): Miltenyi Biomedicine

13.10 Rapcabtagene Autoleucel (YTB323): Novartis

13.11 GLPG5101: Galapagos

13.12 IMPT-314: Lyell/ImmPACT Bio

13.13 AZD0486: AstraZeneca

13.14 Plamotamab: Xencor

14. Diffuse Large B-cell Lymphoma Market: 7MM Analysis

14.1 Key Findings

14.2 Total Market Size of DLBCL in the 7MM

14.3 DLBCL Market Outlook

14.4 Conjoint Analysis

14.5 Key DLBCL Market Forecast Assumptions

14.6 US Diffuse Large B-cell Lymphoma Market Size

14.6.1 Total Market Size of DLBCL in the US

14.6.2 Market Size of DLBCL by Therapy in the US

14.7 EU4 and the UK Market Size

14.8 Japan Market Size

15. Diffuse Large B-cell Lymphoma Unmet Needs

16. Diffuse Large B-cell Lymphoma SWOT Analysis

17. KOL Views on DLBCL

18. DLBCL Market Access and Reimbursement

19. Bibliography

20. DLBCL Market Report Methodology

Related Reports

Diffuse Large B-cell Lymphoma Clinical Trial Analysis

Diffuse Large B-cell Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DLBCL companies, including Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, among others.

Non-Hodgkin's Lymphoma Market

Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others.

Non-Hodgkin's Lymphoma Pipeline

Non-Hodgkin's Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NHL companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., among others.

Follicular Lymphoma Market

Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key follicular lymphoma companies, including Merck Sharp and Dohme, AstraZeneca, CRISPR Therapeutics, BeiGene, Nektar Therapeutics, NovalGen, Carna Biosciences, Allogene Therapeutics, Xynomic Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us Kanishk Kumar info@delveinsight.com +14699457679 www.delveinsight.com